NexGard Combo 3.6 mg + 1.2 mg + 24.9 mg - Spot-on solution
NexGard Combo 3.6 mg + 1.2 mg + 24.9 mg - Spot-on solution
Authorised
- Esafoxolaner
- Eprinomectin
- Praziquantel
Product identification
Medicine name:
NexGard Combo 3.6 mg + 1.2 mg + 24.9 mg - Spot-on solution
Active substance:
- Esafoxolaner
- Eprinomectin
- Praziquantel
Target species:
-
Cat
Route of administration:
-
Spot-on use
Product details
Active substance and strength:
-
EsafoxolanerPresentation_strength:3.6 mg Reference:Hse Index:0
-
EprinomectinPresentation_strength:1.2 mg Reference:Hse Index:1
-
PraziquantelPresentation_strength:24.9 mg Reference:Ph.Eur. Index:2
Pharmaceutical form:
-
Spot-on solution
Withdrawal period by route of administration:
-
Spot-on use
- Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QP54AA54
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Package description:
- Packaging:Spot-on applicator (COC), Package_size:15 applicators, Content:0.3 ml
- Packaging:Spot-on applicator (COC), Package_size:4 applicators, Content:0.3 ml
- Packaging:Spot-on applicator (COC), Package_size:3 applicators, Content:0.3 ml
- Packaging:Spot-on applicator (COC), Package_size:1 applicator, Content:0.3 ml
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Fixed combination application (Article 13b of Directive No 2001/82/EC)
Marketing authorisation holder:
- Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Boehringer Ingelheim Animal Health France
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 15/03/2024
Bulgarian (PDF)
Published on: 15/03/2024
Croatian (PDF)
Published on: 16/11/2022
Czech (PDF)
Published on: 15/03/2024
Danish (PDF)
Published on: 15/03/2024
Dutch (PDF)
Published on: 15/03/2024
Estonian (PDF)
Published on: 16/11/2022
Finnish (PDF)
Published on: 16/11/2022
French (PDF)
Published on: 16/11/2022
German (PDF)
Published on: 15/03/2024
Greek (PDF)
Published on: 15/03/2024
Hungarian (PDF)
Published on: 16/11/2022
Icelandic (PDF)
Published on: 16/11/2022
Italian (PDF)
Published on: 16/11/2022
Latvian (PDF)
Published on: 15/03/2024
Lithuanian (PDF)
Published on: 16/11/2022
Maltese (PDF)
Published on: 15/03/2024
Norwegian (PDF)
Published on: 15/03/2024
Polish (PDF)
Published on: 15/03/2024
Portuguese (PDF)
Published on: 15/03/2024
Romanian (PDF)
Published on: 15/03/2024
Slovak (PDF)
Published on: 15/03/2024
Slovenian (PDF)
Published on: 15/03/2024
Spanish (PDF)
Published on: 16/11/2022
Swedish (PDF)
Published on: 15/03/2024
How useful was this page?:
